ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial

Journal of Clinical Oncology

Volumn 20, Issue 9, 2002, Pages 2240-2250

  Ranson, Malcolm ^a   Hammond, Lisa A ^a   Ferry, David ^a   Kris, Mark ^a   Tullo, Andrew ^a   Murray, Philip I ^a   Miller, Vince ^a   Averbuch, Steve ^a   Ochs, Judy ^a   Morris, Charles ^a   Feyereislova, Andrea ^a   Swaisland, Helen ^a   Rowinsky, Eric K ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; GEFITINIB; GEMCITABINE; NAVELBINE; PROTEIN TYROSINE KINASE INHIBITOR;

ACNE; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED DISEASE; ENZYME INHIBITION; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SOLID TUMOR; TABLET FORMULATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 0036569870     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.10.112     Document Type: Article

References (34)

1. Kinase inhibitors in cancer therapy: A look ahead
2. Epidermal growth factor-related peptides and their receptors in human malignancies
3. Immunohistochemical markers in the morphological diagnosis of lung carcinoma
4. The epidermal growth factor receptor in breast cancen
5. Differential expression of epidermal growth factor receptor in human head and neck cancers
6. The epidermal growth factor receptor (EGFR): A new target in cancer therapy
7. Epidermal growth factor and laminin receptors contribute to migratory and invasive properties of gliomas
8. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt
9. Correlation of cisplatin sensitivity with differential alteration of EGFR expression in head and neck cancer cells
10. Endocrine resistance in breast cancer can involve a switch towards EGFR signalling pathways and a gain of sensitivity to an EGFR-selective tyrosine kinase inhibitor, ZD1839
11. Reduced growth rate accompanied by aberrant epidermal growth factor signalling in drug resistant human breast cancer cells
12. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas
13. Preclinical studies with the oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ('Iressa') demonstrate significant anti-tumor activity
14. Antitumour effect and potentiation of cytotoxic drug activity in human cancer cells by ZD1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
15. ZD1839, an epidermal growth factor tyrosine kinase inhibitor selected for clinical development
16. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of tyrosine kinase
17. Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839
18. Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers
19. Phase I data of ZD1839: An oral epidermal growth factor receptor tyrosine kinase inhibitor
20. A sensitive assay for ZD1839 ('Iressa') in human plasma by liquid-liquid extraction and high performance liquid chromatography with mass spectrometric detection: Validation and use in phase I clinical trials
21. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria
22. Final results from a phase I intermittent dose-escalation trial of ZD1839 ('Iressa') in Japanese patients with various solid tumors
23. A phase I dose-escalation, pharmacokinetic (PK) and pharmacodynamic (PD) study of ZD1839 ('Iressa'): NCIC-CTG IND.122. Poster presented at 11th NCI-EORTC-AACR
24. Continuous administration of ZD1839 ('Iressa'), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumour types: Evidence of activity and good tolerability
25. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225
26. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
27. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck
28. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma
29. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC)
30. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition
31. Potentiation of cytotoxic agents against human tumors in mice by ZD1839 ('Iressa'), an inhibitor of EGFR tyrosine kinase, does not require high levels of expression of EGFR
32. Inhibition of EGFR-tyrosine kinase by ZD1839 ('Iressa') leads to antiproliferative and anitangiogenic effects in human GEO colon cancer xenografts, in combination with paclitaxel
33. Combination of ZD1839 ('Iressa'), an EGFR tyrosine kinase inhibitor, and radiotherapy increases antitumour efficacy in a human colon cancer xenograft model
34. A pilot trial demonstrates the safety of ZD1839 (Iressa), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with carboplatin (C) and paclitaxel (P) in previously untreated advanced non-small cell lung cancer (NSCLC)